Clinical Trial Update: 24-hour Lung Function in Subjects With Moderate to Very Severe COPD After Treatment With PT003, Open-Label Spiriva® Respimat® as an Active Control, and Placebo [Phase 3]

View source ↗

Summary

A Phase 3 study evaluated 24-hour lung function in COPD patients after treatment with PT003, with Spiriva Respimat as an active control and placebo.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• PT003
• SPIRIVA RESPIMAT (tiotropium bromide inhalation spray)

Snippet

Sponsor: Pearl Therapeutics, Inc. | Conditions: COPD | Phase 3 | Status: COMPLETED | Results posted: 2017-04-19